In the latest trading session, 0.47 million ATAI Life Sciences N.V (NASDAQ:ATAI) shares changed hands as the company’s beta touched 1.16. With the company’s most recent per share price at $1.42 changed hands at -$0.08 or -5.00% at last look, the market valuation stands at $239.11M. ATAI’s current price is a discount, trading about -100.7% off its 52-week high of $2.85. The share price had its 52-week low at $1.03, which suggests the last value was 27.46% up since then. When we look at ATAI Life Sciences N.V’s average trading volume, we note the 10-day average is 2.42 million shares, with the 3-month average coming to 1.68 million.
Analysts gave the ATAI Life Sciences N.V (ATAI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATAI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ATAI Life Sciences N.V’s EPS for the current quarter is expected to be -0.15.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Instantly ATAI was in red as seen in intraday trades today. With action -19.49%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 7.14%, with the 5-day performance at -19.49% in the red. However, in the 30-day time frame, ATAI Life Sciences N.V (NASDAQ:ATAI) is -6.86% down. Looking at the short shares, we see there were 10.61 million shares sold at short interest cover period of 5.49 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 76.33% from its recent market value. According to analyst projections, ATAI’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -322.54% plunge from its current level, while the stock would need to soar -322.54% for it to hit the projected low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
Data shows that the ATAI Life Sciences N.V share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -7.47% over the past 6 months, a -208.00% in annual growth rate that is considerably lower than the industry average of 14.30%. Year-over-year growth is forecast to reach 159.03% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 250k. The company’s revenue for the corresponding quarters a year ago was 18k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1,288.89%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 44.19%. The 2025 estimates are for ATAI Life Sciences N.V earnings to decrease by -217.14%.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next quarterly earnings report in February.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.99% of ATAI Life Sciences N.V shares while 26.69% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 29.65%. There are 26.69% institutions holding the ATAI Life Sciences N.V stock share, with WALLEYE CAPITAL LLC the top institutional holder. As of 2024-06-30, the company held 1.7388% of the shares, roughly 2.76 million ATAI shares worth $3.67 million.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 1.7111% or 2.72 million shares worth $3.62 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were iShares Biotechnology ETF and Morgan Stanley Inst Fund Inc-Inception Port. With 794.76 shares estimated at $1.12 million under it, the former controlled 0.47% of total outstanding shares. On the other hand, Morgan Stanley Inst Fund Inc-Inception Port held about 0.31% of the shares, roughly 511.99 shares worth around $0.72 million.
